MDCC Molecular Devices (MM)

SUNNYVALE, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Molecular Devices Corporation (NASDAQ:MDCC), a leader in innovative solutions for drug discovery and life sciences research, today introduced FlexStation(R) 3 next- generation multi-detection benchtop reader with fluidics. FlexStation 3 is based on Molecular Devices' popular SpectraMax(R) M5 multi-detection system with the addition of liquid handling. The system was developed for use in research, assay development and lead optimization environments to address applications for researchers performing assay development and small-scale screens. FlexStation 3 will debut today at the Annual Meeting of the Society for Biomolecular Sciences (SBS) in Seattle, Washington, in Molecular Devices Booth #2501. FlexStation 3 addresses a wide variety of assays that require liquid handling, including fast kinetic assays such as calcium mobilization or dual luciferase reporter gene, as well as traditional endpoint or slow kinetic assays requiring automation liquid transfer prior to plate reading. The system uses an 8- or 16-channel pipettor head to transfer reagents from 96 or 384 distinct wells of a source plate to a read plate, simultaneously. Direct transfer reduces reagent consumption and allows more assay conditions to be explored in a single microplate, making the system more amenable to agonist and antagonist assay formats. In addition, with integrated pipetting, researchers can adjust dispense parameters to optimize the assay's robustness, such as accommodating cells with different adherence characteristics or adjusting dispense speed to provide adequate mixing. Jennifer McKie, Director of Marketing at Molecular Devices, commented, "The FlexStation 3 next-generation system is an improved version of our FlexStation II instrument, and is based on the proven optics of our powerful SpectraMax M5 multi-detection reader. FlexStation 3 will address more applications in different modes, particularly fast luminescence and absorbance assays. The system also has increased reliability since the 8- and 16-channel pipettor heads are more accurately aligned to the tip racks, enabling customers to more reliably and easily change pipettor heads." McKie continued, "In addition, disposable tips minimize carry-over between plates and experiments, as well as making the system easy to clean." Molecular Devices Corporation is a leading supplier of high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. The Company's systems and consumables enable pharmaceutical and biotechnology companies to leverage advances in genomics, proteomics and parallel chemistry to facilitate the high-throughput and cost-effective identification and evaluation of drug candidates. The Company's solutions are based on its advanced core technologies that integrate its expertise in engineering, molecular and cell biology and chemistry. Molecular Devices enables its customers to improve research productivity and effectiveness, which ultimately accelerates the complex process of discovering and developing new drugs. This press release contains "forward-looking" statements, including statements related to the prospects for or potential customer use of FlexStation 3. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Molecular Devices Corporation to differ materially from those indicated by these forward-looking statements, including, among others, risks related to the development of new products and their commercial acceptance, and other risks detailed from time to time in Molecular Devices' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2006. Molecular Devices Corporation does not undertake any obligation to update forward- looking statements. DATASOURCE: Molecular Devices Corporation CONTACT: Tim Harkness of Molecular Devices Corporation, +1-408-747-3533 Web site: http://www.moleculardevices.com/

Copyright